( BLOOMFIELD N.J. March 26 2007 /PRNe...)In vivo Study Results Demonstrating Potential of Alfacell's,Onconase for Treatment of Non-Small Cell Lung Cancer Published in,Anticancer Research,Health

BLOOMFIELD, N.J., March 26, 2007 /PRNewswire-FirstCall/ -- Alfacell Corporation today announced that in vivo study results demonstrating the potential of ONCONASE (ranpirnase) for the treatment of non-small cell lung cancer (NSCLC) were recently published in Anticancer Research (2007; 27: 299- 308).

Based on the work of Intae Lee, Ph.D., at the University of Pennsylvania, a paper entitled "Antitumor Efficacy of the Cytotoxic RNase, Ranpirnase, on A549 Human Lung Cancer Xenografts of Nude Mice" shows that:

    * ONCONASE significantly inhibited tumor growth of A549 NSCLC cells both

      in vitro and in vivo; apoptosis was significantly induced by ONCONASE in

      a dose-dependent manner


    * Multiple small doses of ONCONASE were more effective than one large

      single dose of ONCONASE for the inhibition of tumor growth in animal

      studies


    * ONCONASE in combination with cisplatin significantly reduced tumor

      growth of A549 cells; in large tumors, including those unsuccessfully

      treated with cisplatin previously, ONCONASE demonstrated inhibition of

      tumor growth

"ONCONASE has important potential clinical uses for the treatment of NSCLC," said Dr. Lee. "We are pleased that the results of our studies have helped to guide the clinical development of ONCONASE for NSCLC."

Kuslima Shogen, Alfacell's chairman and chief executive officer, said, "The publication of this paper in an important peer-reviewed journal is further recognition of the potential of ONCONASE. This data is evidence that ONCONASE has the potential to overcome resistance to, and enhance the performance of, cisplatin. We expect to continue advancing ONCONASE through the development process as we work to build a broad franchise in different therapeutic areas and via multiple treatment modalities."

About ONCONASE(R)

ONCONASE is a first-in-class therapeutic based on Alf
'"/>